Skip to main content
. 2011 Nov;9(3-4):111–118. doi: 10.3121/cmr.2011.907

Table 2.

Overview of all patient characteristics.

Tumor subtypes No. of patients (%)
ER status
 Positive 318 (74.7%)
 Negative 108 (25.4%)
PR status
 Positive 242 (56.8%)
 Negative 184 (43.2%)
HER2 immunohistochemistry
 Positive 88 (20.7%)
 Negative 338 (79.3%)
Triple negative status
 Positive 62 (14.6%)
 Negative 364 (85.4%)
Blood group
 A 198 (46.5%)
 B 43 (10.1%)
 AB 22 (5.2%)
 O 163 (38.3%)